YTYuya Terajima

Yuya Terajima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuya Terajima has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Eri Katsuyama

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama

    3 shared publications
  • Jun Wada

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

    3 shared publications
  • Kazuya Matsumoto

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama

    3 shared publications
  • Kei Hirose

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama

    3 shared publications
  • Natsuki Kubota

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama

    3 shared publications
  • Takayuki Katsuyama

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama

    3 shared publications

Latest Publications

  • Open Access

    Sjögren disease and idiopathic inflammatory myopathy overlap presenting as complement-mediated thrombotic microangiopathy/atypical haemolytic uremic syndrome with a complement factor B variant: A case report

    by Momoka Hasegawa, Yoshia Miyawaki, Moe Sakamoto-Tokunaga, Masaki Matoba, Megumi Maeda, Tomokazu Tamura, Natsuki Kubota, Yuya Terajima, Kei Hirose, Kazuya Matsumoto, et al.

    Complement-mediated thrombotic microangiopathy (CM-TMA) is often triggered by autoimmune diseases; however, reports of CM-TMA in patients with Sjögren disease and idiopathic inflammatory myopathy are limited. We describe the case of a 48-year-old woman with overlapping Sjögren disease and idiopathic inflammatory myopathy who presented with interstitial lung disease. After the initiation of combination therapy with a calcineurin inhibitor, intravenous cyclophosphamide, and glucocorticoids, she developed progressive thrombocytopenia with schistocytosis, haemolytic anaemia, and acute renal dysfunction. Laboratory testing revealed preserved disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13) activity (49%) with negative ADAMTS13 inhibitor and Shiga toxins. Despite therapeutic plasma infusion and plasma exchange, she developed severe cardiac dysfunction and abdominal pain, with progressive haematologic and renal dysfunctions requiring haemodialysis. Based on a clinical diagnosis of CM-TMA, eculizumab was initiated, resulting in gradual improvement in haemolysis markers and platelet counts. However, she developed severe multiorgan complications, including a cerebellar haemorrhage, acute pancreatitis, and coagulopathy, and ultimately died. Genetic testing performed during the clinical course identified a complement factor B p.Arg74His variant. This case represents an instance of CM-TMA associated with a Sjögren disease/idiopathic inflammatory myopathy overlap and a complement factor B variant of uncertain pathogenic significance, suggesting that multiple converging factors may contribute to CM-TMA development.

  • Open Access

    Dental infection is associated with early relapse in patients with ANCA-associated vasculitis

    by Shoichi Nawachi, Takayuki Katsuyama, Yoshia Miyawaki, Moe Sakamoto-Tokunaga, Natsuki Kubota, Yuya Terajima, Kazuya Matsumoto, Kei Hirose, Takato Nakadoi, Manami Hirata-Watanabe, et al.

    Objectives: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections can trigger relapses. Dental infections, being common and associated with systemic inflammation, may play a role in AAV relapse, though their impact remains unclear. We aimed to evaluate the association between severe dental infections and early relapse in patients with AAV. Methods: This retrospective cohort study included patients newly diagnosed with AAV between January 2011 and July 2022. Patients with severe dental infections requiring tooth extraction were placed in the dental infection group, while the remaining patients were assigned to the control group. The primary outcome was defined as either vasculitis relapse or all-cause mortality within 1 year of treatment initiation. Adjusted HRs (aHRs) and 95% CIs were estimated using Cox proportional hazards models. Results: A total of 93 patients were enrolled with a median age of 74 years. 41 patients (44.1%) had severe dental infections in this cohort. Over the 1-year follow-up period, 13 patients experienced a relapse and two died, resulting in a composite event rate of 20.9 per 100 person-years. Dental infection was independently associated with the composite outcome (aHR, 3.78 (95% CI 1.13 to 12.66); p=0.031). Exploratory analysis indicated that composite outcome rates were similar regardless of tooth extraction among patients with dental infections. Conclusions: Severe dental infections were associated with increased risk of early relapse or mortality in AAV. These findings highlight the importance of early dental evaluation in AAV management.

  • Association of anti-citrullinated protein antibodies with changes in bone density in patients with rheumatoid arthritis treated with romosozumab for one year: A cohort study

    by Yuya Terajima, Yoshia Miyawaki, Koji Takasugi, Ryozo Harada, Wataru Yamamoto, Kazuhiko Ezawa, Natsuki Kubota, Kazuya Matsumoto, Kenta Shidahara, Kei Hirose, et al.